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Aims: Lymphangiogenesis, the formation of new lymphatic vessels, is thought to constitute a route for the tumor
cells to metastasize. We previously demonstrated that endothelin-1 (ET-1) induces the expression of
lymphangiogenic factors through hypoxia-inducible factor (HIF)-1α and HIF-2α. The stability of these transcrip-
tional factors is essential for lymph/angiogenesis and tumor progression. Here we analyze the molecular
mechanism through which ET-1 regulates HIF-1α and HIF-2α protein levels and how these transcriptional
factors are implicated in controlling lymphatic endothelial cell (LEC) behavior.
Main methods: Using Western blotting assay and a reporter gene containing the HIF-1α oxygen-dependent
degradation domain we monitored the capacity of ET-1 to increase HIF-1α and HIF-2α stability and nuclear
accumulation. In addition, using siRNA against HIF-1α or HIF-2α, we investigated the implication of these tran-
scriptional factors in ET-1-mediated tube-like structure formation. As HIF-1α proteosomal degradation is con-
trolled by site-speciﬁc hydroxylation carried out by HIF-prolyl hydroxylase domain (PHD) enzymes, we
analyzed the expression of PHD-2 isoform.
Key ﬁndings:We show that ET-1 through its receptor, ETBR, controls HIF-α stability and nuclear accumulation by
inhibiting prolyl hydroxylation and reduces PHD2mRNA and protein levels. Transfection with HIF-1α or HIF-2α
siRNA abrogated the capacity of ET-1 to induce tube-like structure formation.
Signiﬁcance: These results reveal a PHD2-mediatedmechanism throughwhich ET-1 stabilizesHIF-1α andHIF-2α
pathway thereby regulating LEC behavior and lymphangiogenesis.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Lymphangiogenesis refers to the formation of new lymphatic vessels
that occurs during tumor growth and is thought to constitute conduits
for the tumor cells tometastasize (Alitalo and Detmar, 2012). Therefore,
elucidation of mechanisms regulating lymphatic vessel growth is a
critical step toward developing therapeutic interventions aimed at
preventing lymphatic metastases (Alitalo et al., 2005). Recently, several
growth factors have been shown to be implicated in mediating
lymphangiogenesis (Cao et al., 2006; Cao et al., 2012; Alitalo and
Detmar, 2012). In particular we demonstrated that endothelin (ET)-1@ifo.it (F. Spinella).
lecular Pathology, Regina Elena
e, Italy.
. This is an open access article underthrough its binding with ETB receptor (ETBR) expressed on lymphatic
endothelial cells (LEC), induced cell growth and invasiveness directly
and in a vascular endothelial growth factor (VEGF)-mediated manner
(Spinella et al., 2009; Garrafa et al., 2012). ET-1-induced effects on LEC
were abolished by ETBR antagonists, suggesting that this receptor may
represent a potential target to inhibit lymphangiogenesis (Rosanò
et al., 2013; Cueni et al., 2010).
Hypoxia-inducible factor-1α (HIF)-1α and HIF-2α are transcrip-
tion factors that play a central role in coordinating angiogenesis
(Semenza, 2012). In normoxic conditions, HIF-1α and HIF-2α are de-
graded by a mechanism involving hydroxylation of 2 proline resi-
dues, by HIF-prolyl hydroxylase domain (PHD), ubiquitylation, and
proteosomal degradation (Metzen et al., 2005). Hypoxia and angio-
genic stimuli stabilize HIF-1α, enabling dimerization with HIF-1β,
nuclear translocation, and activation of HIF-1α/β-responsive ele-
ments in target genes. In this manner, the cascade of target gene
transcription by HIF-1α coordinates diverse physiological events,
such as cellular migration, proliferation, and tubule formation,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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and Ratcliffe, 2008).
The PHD family is comprised of three bona ﬁde HIF prolyl hydroxy-
lases (PHD1, PHD2, and PHD3), among these PHD2 has been proposed
to be the key oxygen sensor for setting steady-state levels of HIF-1α
(Berra et al., 2003). In this regard we previously demonstrated that
PHD2mediates ET-1-induced HIF-1α and HIF-2α stability inmelanoma
cells (Spinella et al., 2010). More recently it has been shown that ET-1
induces a pulmonary arterial endothelial and smooth muscle cells
(PASMC)-speciﬁc increase in HIF-1α levels by upregulation of HIF-1α
synthesis and downregulation of PHD2-mediated degradation, thereby
amplifying the induction of HIF-1α in PASMCs during moderate,
prolonged hypoxia (Pisarcik et al., 2013). To date, relatively little is
known about the ability of the individual members of the PHD family
to control HIF-1α and HIF-2α in LEC.
Here we demonstrate that in LEC ET-1 induces HIF-1α and HIF-2α
stabilization and nuclear accumulation by impairing their degradation.
Using siRNA against HIF-α subunits, we show that HIF-1α and HIF-2α
play a key role in coordinating and initiating lymphangiogenesis by
regulating migration and sprouting of LEC. Therefore in this study we
deﬁned the molecular mechanism through which ET-1 controls HIF-1α
and HIF-2α and identiﬁed PHD2 as potential regulator of HIF-1α and
HIF-2α-mediated ET-1 lymphangiogenic activities.
Material and methods
Lymphatic endothelial cell puriﬁcation and cell cultures
Human lymph node specimens were obtained according to the
guidelines of Helsinki Declaration from patients undergoing surgical
procedures for non-infectious or neoplastic conditions. Lymph nodal
LEC were isolated as previously described (Garrafa et al., 2005; Garrafa
et al., 2006; Spinella et al., 2009) from a pool of three patients. Cells
were grown on collagen type I-coated ﬂasks (5 μg/cm2; Boehringer
Mannheim) in EGM-2 MV (Lonza, Basel Switzerland). For the HIF-1α
and HIF-2α stability study cycloheximide (CHX, 100 μM, SIGMA) was
added after 24 h of ET-1 or hypoxic treatment, and the cellswere further
incubated under normoxia for varying times in the presence of CHX. To
expose cells to hypoxia, a modular incubator was used with an atmo-
sphere setting of 5% CO2, 95% N2, and 1% O2. ET-1 (Peninsula Laborato-
ries, Belmont, CA) was used at 100 nM. When BQ788 (1 μM; Peninsula
Laboratories) was tested, it was added 30 min before the stimuli.
Transfection and luciferase assay
Transfection experiments employed the Lipofectamine reagent
(Invitrogen, Grand Island, NY, USA) according to the manufacturer's
protocol. For the silencing, small interfering RNA (siRNA) duplexes
against human ETBR, HIF-1α or HIF-2αmRNA (100 nM) (SMARTpool;
Dharmacon, Lafayette, CO) were used. Non-target control siRNAs
(Dharmacon) were used as control. After 48 h cells were used for 24 h
treatment with ET-1 or hypoxia. Each knockdown experiment de-
scribed herein was detected for a speciﬁc reduced expression of ETBR,
HIF-1α, or HIF-2α mRNA by quantitative real time PCR. For plasmid
1 μg of vectors encoding CMV-Luc-ODDD (Dr. R. K. Bruick, University
of Texas Southwestern Medical Center, TX) in combination with the
pCMV-β-galactosidase plasmid (Promega, Corporation, Madison, WI)
were used. Luciferase activities were measured with Luciferase assay
system (Promega).
Western blot analysis
Cells were lysed in lysis buffer [250 mM NaCl, 50 mM HEPES
(pH 7.4), 1 mM ethylenediaminetetraacetic acid (EDTA), 1% Nonidet
P-40, protease inhibitors]. NE-PERnuclear and cytoplasmic extraction re-
agents (Thermo Fisher Scientiﬁc, Illkirch-Cedex France) were used toseparate cytoplasmic and nuclear fractions. Whole cell lysates or nuclear
extracts were subjected to SDS-PAGE and analyzed by Western blotting.
Blots were developed with the enhanced chemiluminescence detection
system (ECL; Amersham Pharmacia Biotech, Buckinghamshire, UK).
Antibody against PHD2 was from Novus Biologicals (Littleton, CO);
β-actin, used as loading control, was from Oncogene (CN Biosciences,
Inc., Darmastadt, Germany); and anti-PCNA and anti-HSP70 (Santa
Cruz, Aachen, Germany) were used to verify the purity of nuclear
fractions.
Quantitative real-time-PCR
Total RNA was isolated using the TRIzol (Invitrogen) according to
the manufacturer's protocol. Five μg of RNA was reversed transcribed
using the SuperScript® VILO™ cDNA synthesis kit (Invitrogen). Quanti-
tative real-time-PCRwas performed by using the LightCycler rapid ther-
mal cycler system (Roche Diagnostics, Mannheim, Germany) according
to themanufacturer's instructions. Reactionwas performed in 20 μl vol-
ume with 0.3 μM primers, by using the LightCycler-FastStart DNAMas-
ter Plus SYBR Green mix (Roche Diagnostics) from 1 μl cDNA under the
following conditions: denaturation at 95 °C for 5 min; melting at 95 °C
for 10 s; annealing between 58 °C for 10 s; extension at 72 °C for 10 s.
Primers used were as follows: PHD2, (forward) 5′-GCACGACACCGGGA
AGTT-3′, (reverse) 5′-CCAGCTTCCCGTTACAGT-3′; HIF-1α (forward)
5′-CAAGTCACCACAGGACAG-3′, (reverse) 5′-AGGGAGAAAATCAAGT
CG-3′; HIF-2α (forward) 5′-TGATTTCCTGTGTGTGTTGC-3′, (reverse)
5′-CGTTACGTTGACAGGTAGGG-3′ and cyclophilin-A, (forward) 5′-
TTCATCTGCACTGCCAAGAC-3′, and (reverse) 5′-TGGAGTTGTCCACAGT
CAGC-3′. The number of each gene-ampliﬁed product was normalized
to the number of cyclophilin-A ampliﬁed product and results were
expressed as fold induction compared to the control.
In vitro tube formation assay
Tube forming activity was analyzed as previously described
(Spinella et al., 2009). In brief, 50 μl of Matrigel (Cultrex, basal mem-
brane extract, Trevigen, 12.7 mg/ml) was dropped onto each well of a
96-well plate andwas allowed to solidify for 1 h at 37 °C in a humidiﬁed
5% CO2 incubator. LEC at 1 to 5 × 104 were plated and the cells were
cultured under normoxia or hypoxia. Formation of tube-like structures
was photographed after 24 h using light microscopy and quantiﬁed by
counting the number of tubule intersections in 10 randomly chosen
ﬁelds using the Scion image analysis program. Magniﬁcation ×20.
Statistical analysis
Each experiment was repeated at least three times with comparable
results, unless indicated otherwise. Statistical analysis was carried out
by using the Student's t test or one-way analysis of variance (ANOVA)
as appropriate. All statistical tests were two-sided and were performed
using the PRISM software (GraphPad Prism version 5.0, Software, Inc.,
San Diego, CA). p values were signiﬁcant at p b 0.05.
Results
ET-1 induces HIF-1α and HIF-2α stabilization through ETBR
To assess whether ET-1 regulated the expression of HIF-1α and
HIF-2α protein by inhibiting its degradation, we monitored the levels
of protein after protein synthesis blockade by cycloheximide (CHX), as
positive control LEC were exposed to hypoxia. Cells were treated with
ET-1 (100 nM) or exposed to hypoxia (1% O2) for 24 h and then trans-
ferred to normoxia and cultured in the presence of CHX for the indicat-
ed times. As shown in Fig. 1A, ET-1 or hypoxia markedly increased the
HIF-1α and HIF-2α protein levels. After removing ET-1 the levels of
ET-1-induced HIF-1α and HIF-2α decayed after 120 min, while that
Fig. 1. ET-1 induces HIF-1α and HIF-2α stabilization and nuclear accumulation through ETBR. (A) LEC were stimulated with ET-1 (100 nM) or hypoxia (1% O2) for 24 h. After that cyclohex-
imide (CHX) was added and cells were transferred under normoxic conditions. Total cell lysates were analyzed for HIF-1α and HIF-2α protein expression byWestern blotting assay, β-actin
was used as loading control. The average of HIF-1α and HIF-2α shown in the graphics corresponds to the quantiﬁcation of protein bands in images, normalized to β-actin content ± SD.
(B) LEC were stimulated with ET-1 (100 nM) alone or in combination with BQ788 (1 μM) and after 6 h nuclear extracts were analyzed by Western blotting for HIF-1α. Proliferating cell
nuclear antigen (PCNA) antibody was used as loading control and HSP70 to verify the purity of nuclear extracts. The average of nuclear HIF-1α shown in the graphics corresponds to the
quantiﬁcation of protein bands in images from three independent experiments, normalized to PCNA content ±SD. *p b 0.05 (versus control); **p b 0.01 (versus ET-1).
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60 min (Fig. 1A). Densitometry analysis showed that the accumulation
of HIF-1α induced by hypoxic stimulus (Fig. 1A left panel) or ET-1 treat-
ment (Fig. 1A right panel) promoted both HIF-1a and HIF-2a accumula-
tions, although the levels of HIF-2α were increased to a minor extent.
Next, to test whether HIF-1α accumulation resulted in an increased
nuclear translocation, nuclear extracts from LEC stimulatedwith the se-
lective ETBR antagonist BQ788 alone or in combination with ET-1 were
analyzed byWestern blotting. As shown in Fig. 1B while ET-1 induced a
strong induction ofHIF-1α nuclear accumulation the presence of BQ788
inhibited this effect. Densitometric analysis showed that ET-1-induced
HIF-1α nuclear accumulation (2 fold versus the control) was reduced
(1.2 fold compared to the control) by BQ788, demonstrating that ET-1
increases HIF-1α stabilization and nuclear translocation through ETBR.ET-1 induces LEC migration and cord formation via HIF-1α and HIF-2α
Despite the large evidence that endothelial cells showed a similar re-
sponse to ET-1 and to hypoxia in terms of angiogenic factor production
and cord formation induction (Spinella et al., 2002; Spinella et al., 2009,
Garrafa et al., 2012), little is known about the molecular mechanism
that transduces these processes. Thereforewe assessedwhether the ob-
served increase in HIF-1α and HIF-2α stabilization may be responsible
for ET-1-dependent induction of LEC capillary morphogenesis. To this
end we transfected LEC with siRNA oligonucleotides targeting HIF-1αand HIF-2α and cells were stimulated with ET-1. After 16 h mRNA
was analyzed by real time PCR. Transfection led to inhibition of the cor-
responding mRNA expression (Fig. 2A and B) in both unstimulated and
ET-1 stimulated cells. In particular HIF-1α andHIF-2αmRNA levels were
inhibited by 70% and 80% respectively (Fig. 2A). In contrast, a scramble
siRNA used as negative control (SRC) did not affect mRNA expression of
either HIF-1α and HIF-2α. To investigate the involvement of HIF-1α
and HIF-2α in the ET-1 induction of cord formation, LEC untransfected
or transfected with SRC or siRNA targeting HIF-1α or HIF-2 were seeded
on Matrigel and stimulated with ET-1 for 24 h. Unstimulated LEC formed
few cords while under ET-1 stimulation we observed the formation of a
rich network of tubular structures. Transfection of siRNA oligonucleo-
tides targeting HIF-1α or HIF-2α signiﬁcantly (p b 0.01) reduced cord
formation induced by ET-1. Consistently, quantiﬁcation analysis demon-
strated a reduction of junction number in that cells silenced for HIF-1α
and HIF-2α (Fig. 2C) indicating that these transcriptional factors are re-
quired for ET-1 induction of cord in LEC.ET-1 induces PHD2 inhibition through ETBR
Under normoxic conditionsHIF-1α andHIF-2αproteins are degraded
by PHDhydroxylation occurring on their oxygen-dependent degradation
domain (ODDD) encompassing the PHD-targeted prolines (Metzen et al.,
2005). To further investigate the role of ET-1 on the stability of HIF-αwe
used a reporter plasmid expressing HIF-α-ODDD fused with luciferase
Fig. 2.HIF-1α and HIF-2α siRNA inhibit cord formation induced by ET-1. (A) LEC were transfected with a negative control scramble (SCR) or siRNA for HIF-1α or HIF-2α. Cells were then
treated with ET-1 100 nM for 24 h and HIF-1α and HIF-2α mRNAs were analyzed by real time PCR. Results are expressed as copy numbers of HIF-1α and HIF-2α transcripts over
cyclophilin-A. Bars,±SD. *, p b 0.05 compared to the control. (B) PCR products for HIF-1α, HIF-2α and cyclophilin-A. (C) LEC transfectedwith the indicated siRNAwere seeded onMatrigel
in serum-free media in the presence or absence of ET-1 (100 nM) under normoxic conditions for 24 h and cord formation was examined. Quantiﬁcation analysis was performed by
measuring the number of intersections. Data are means ± SD. *p b 0.05 (versus control); **p b 0.01 (versus ET-1).
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for different times with ET-1 or cultured under hypoxia. As shown in
Fig. 3A, luciferase-ODDD stabilization increased in a time-dependent
manner after stimulation with ET-1 with maximal levels obtained
at 6 h. These effects were blocked by BQ788 (Fig. 3B). We next evaluated
the oxygen sensing enzymes that may be implicated in regulating HIF-α
stability. To this end we focalized our attention on PHD2, and analyzedFig. 3. ET-1 induces HIF-1α and HIF-2α protein stability by impairing PHD2-mediated HIF
were treated for different times with ET-1 or hypoxia (H) (A), or pretreated with BQ788
β-galactosidase, and results were expressed as fold induction compared to the control. Bars,
with ET-1 alone or in combination with BQ788 for 6 h and cell lysates were analyzed for PHD2its expression at mRNA and protein levels. As found by real time PCR
and Western blotting, ET-1 signiﬁcantly decreased PHD2 mRNA
and protein levels (Fig. 3C and D), this effect was impaired by BQ788, in-
dicating that ETBR activation speciﬁcally inhibits PHD2. Our results pro-
vide the evidence that ET-1 controls HIF-1α and HIF-2α stability
through a mechanism that involves prolyl hydroxylase-dependent
degradation.α hydroxylation. LEC were transfected with CMV-Luc-ODDD construct. After 24 h cells
alone or with ET-1 for 6 h (B). Luciferase activity was measured, normalized against
±SD. *, p b 0.01 compared to control; **, p b 0.001 compared to ET-1. LEC were treated
expression by real time PCR (C) and Western blotting assay (D).
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Clinical cancer studies have shown a correlation between tumor
hypoxia, HIF-1α expression, and lymphatic metastases (Schindl et al.,
2002; Kurokawa et al., 2003; Katsuta et al., 2005; Schito et al., 2012;
Hanna et al., 2013). Similarly, animal studies have shown that HIF-1α
blockade reduces lymphatic metastasis, which suggests that HIF-1α
regulates tumor-associated lymphangiogenesis and that targeting
HIF-1α may represent a potential therapeutic strategy to modulate
lymphangiogenesis (Yeo et al., 2003; Shin et al., 2007). PHDs func-
tion as negative regulators of HIF-1α or HIF-2α thereby suggesting
that the inactivation of PHD may provide a critical mechanism in
modulating HIF-α. Until now very little is known regarding the
molecular regulation of PHD and on its role in controlling HIF-1α
and HIF-2α in lymphangiogenesis. Here we provide a mechanism
controlled by ET-1 inwhich the increased stability and nuclear accumu-
lation of HIF-1α and HIF-2α are tightly regulated by a prolyl hydroxyl-
ation enzymatic reaction and are involved in ET-1-induced LEC
migration and cord formation.
We previously demonstrated that in LEC ET-1, similar to hypoxia, in-
creases the expression of HIF-1α protein (Spinella et al., 2009). In this
study by examining the kinetics of ET-1-induced HIF-1α and HIF-2α
protein we observed that ET-1 increased HIF-1α and HIF-2α stability.
Many activators of HIF-1, including hypoxia, have been shown to induce
HIF-1 protein expression by inhibiting ubiquitination and degradation
(McMahon et al., 2006; Berchner-Pfannschmidt et al., 2007). Our results
demonstrated that ET-1 shares mechanistic similarities with hypoxia
regulating prolyl hydroxylation of HIF-α subunits. Indeed, treatment
with ET-1 increased in a time-dependent manner the integrity of a
construct containing the ODD domain of HIF-α protein targeted by
prolyl hydroxylase enzymes and prevented its proteosomal degrada-
tion. This effect was speciﬁc as demonstrated by the use of BQ788 that
inhibited the effect of ET-1. Recent studies have highlighted the
importance of PHD2, the key oxygen sensor in controlling both tumor
angiogenesis, vascular normalization and neovascularization (Chan
and Giaccia, 2010).
Investigating the molecular mechanism that controls ET-1-reduced
HIF-1α and HIF-2α hydroxylation we found that ET-1 reduced PHD2
expression. These results deﬁne the HIF-1α hydroxylase pathway as
the link between ET-1 axis and the regulation of HIF-1α stabilization.
In this regard, our previous results demonstrated that the overex-
pression of PHD2 in tumor cells suppressed HIF-1α and HIF-2α accu-
mulation and secretion of VEGF, while, PHD2 silencing stimulated
VEGF leading to increased formation of cord-like structures in HUVEC
(Spinella et al., 2010). Thus our present results in LEC further support
the hypothesis that ET-1-mediated inhibition of PHD2 expression may
be a conserved mechanism regulating HIF-1α in a variety of settings,
including blood and lymphatic endothelial cells.
Genetic studies with endothelial cell-speciﬁc deletion of HIF-1α or
HIF-2α, strongly suggest that these transcriptional factors have impor-
tant non-redundant roles and are concomitantly required for the
maintenance of endothelial cells (Skuli et al., 2012; Han et al., 2012).
Moreover, recent studies reported that rapid degradation of HIF-1α
may impair lymphangiogenesis during wound-healing assay (Zampell
et al., 2012) and that HIF-2α is required for the induction of migration
(Han et al., 2012) suggesting that HIF-1α and HIF-2αmay play a direct
role in modulating LEC behavior. Our ﬁndings demonstrated that
silencing of HIF-1α and HIF-2α impairs the capacity of ET-1 to induce
cell and organize vascular-like structure formation, demonstrating the
key role of these transcriptional factors in LEC responses to ET-1. We
previously demonstrated that ET-1 regulates VEGF-A and VEGF-C ex-
pression through HIF-1α and HIF-2α in tumor cells (Spinella et al.,
2013). Moreover in LEC HIF-1α silencing impaired the capacity of ET-1
to induce VEGF (Spinella et al., 2009) and blockade of VEGF-A pathway
reduces the capacity of ET-1 to promote the formation of tube-like struc-
tures on LEC (Garrafa et al., 2012). Moreover, a recent report indicatedthat the ET-1-induced HIF-1α stability is involved in VEGF-mediated an-
giogenic processes (Wu et al., 2013). In this regard, it has been
demonstrated that up-regulation of ET-1 may also implicate tumor
lymphangiogenesis (Cueni et al., 2010). Thus it is possible to speculate
that ET-1-induced HIF-1α stabilizationmay represent a critical regulato-
ry step in the initial expression of VEGF during angiogenesis and
lymphangiogenesis.
The results of our study identiﬁed in ETBR a potential therapeutic
target to block ET-1-induced HIF-1α stability thereby regulating LEC
behavior.
Conclusions
Similar to angiogenesis, our results demonstrate that the process of
ET-1-induced lymphangiogenesis is ﬁnely tuned by HIF-1α and
HIF-2α that may directly regulate LEC behavior other than regulating
speciﬁc target genes, such as VEGF members. In view of the molecular
mechanism that we deﬁned the present results raise the possibility
that ETBR activation contributes to lymphangiogenesis through a HIF-α
transcriptional signaling controlled by PHD2-mediated HIF-1α and
HIF-2α stability on LEC. Thus ETBR antagonists, which have been
shown to induce concomitant anti-tumor activity and suppression of
neovascularization (Spinella et al., 2009; Spinella et al., 2013), may
therefore represent a targeted therapeutic approach for the prevention
of tumor spreading.
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